Zosuquidar trihydrochloride
zosuquidar trihydrochloride is a difluorocyclopropyl quinoline. Zosuquidar trihydrochloride binds with high affinity to P-glycoprotein and inhibits P-glycoprotein-mediated multidrug resistance (MDR). P-glycoprotein, encoded by the MDR-1 gene, is a member of the ATP-binding cassette superfamily of transmembrane transporters and prevents the intracellular accumulation of many natural product-derived cytotoxic agents.
zosuquidar trihydrochloride, Bulk in stock, contact us by email for the quotation.
仅供研究使用。 我们不向患者出售。
化学信息
| 名称 | Zosuquidar trihydrochloride |
|---|---|
| Iupac 化学名称 | (2R)-1-{4-[(1aR,6r,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol trihydrochloride |
| 同义词 | LY 335979; LY-335979; LY335979; D06387; RS33295198; Zosuquidar HCl; Zosuquidar 3HCl; Zosuquidar trihydrochloride |
| 英文同义词 | LY 335979; LY-335979; LY335979; D06387; RS33295198; Zosuquidar HCl; Zosuquidar 3HCl; Zosuquidar trihydrochloride |
| 分子式 | C32H31F2N3O2.3HCl |
| 分子量 | 636.99 |
| Smile | c1ccc2c(c1)[C@@H](c3ccccc3[C@@H]4[C@H]2C4(F)F)N5CCN(CC5)C[C@H](COc6cccc7c6cccn7)O |
| InChiKey | IHOVFYSQUDPMCN-DBEBIPAYSA-N |
| InChi | InChI=1S/C32H31F2N3O2/c33-32(34)29-22-7-1-3-9-24(22)31(25-10-4-2-8-23(25)30(29)32)37-17-15-36(16-18-37)19-21(38)20-39-28-13-5-12-27-26(28)11-6-14-35-27/h1-14,21,29-31,38H,15-20H2/t21-,29-,30+,31-/m1/s1 |
| Cas号 | 167465-36-3 |
| MDL | MFCD09837761 |
| 相关CAS号 | 167465-36-3 ( HCl) 167354-41-8 (free base) |
订购信息
| 包装 | 价格 | 库存 | 纯度 | 备货期 |
|---|---|---|---|---|
| 大货 | 询价 | 询价 | 询价 |
| 外观性状 | light yellow to off-white solid |
|---|---|
| 纯度 | 99% |
| 存储 | 3 years -20ºCpowder 6 months-80ºCin solvent |
| 可溶性 | 5mg/ml in DMSO |
| 处理方式 | |
| 运输条件 | Shipped under ambient temperature |
| 海关编码 |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |
1. Alam A, Küng R, Kowal J, McLeod RA, Tremp N, Broude EV, Roninson IB, Stahlberg H, Locher KP.，Structure of a zosuquidar and UIC2-bound human-mouse chimeric ABCB1. Proc Natl Acad Sci U S A. 2018 Feb 27;115(9):E1973-E1982. doi: 10.1073/pnas.1717044115. Epub 2018 Feb 13.
2. Battistella C, Klok HA.，Reversion of P-gp-Mediated Drug Resistance in Ovarian Carcinoma Cells with PHPMA-Zosuquidar Conjugates. Biomacromolecules. 2017 Jun 12;18(6):1855-1865. doi: 10.1021/acs.biomac.7b00291. Epub 2017 May 4.
3. Abu Ajaj K1, Graeser R, Kratz F.，Zosuquidar and an albumin-binding prodrug of zosuquidar reverse multidrug resistance in breast cancer cells and an albumin-binding prodrug. Breast Cancer Res Treat. 2012 Jul;134(1):117-29. doi: 10.1007/s10549-011-1937-9. Epub 2012 Jan 8.
4. Briglia M, Fazio A, Faggio C, Lang F.，Triggering of Suicidal Erythrocyte Death by Zosuquidar.
Cell Physiol Biochem. 2015;37(6):2355-65. doi: 10.1159/000438589. Epub 2015 Dec 7.
Abstract
BACKGROUND:
The P-glycoprotein inhibitor zosuquidar (LY335979) is clinically used to augment the effect of cytostatic drugs on suicidal tumor cell death or apoptosis. The present study explored whether the substance is cytotoxic to erythrocytes. Upon injury, erythrocytes may undergo suicidal cell death or eryptosis, which is characterized by cell shrinkage and translocation of cell membrane phosphatidylserine to the erythrocyte surface. Signaling of eryptosis include increase of cytosolic Ca2+-activity ([Ca2+]i), oxidative stress and activation of several kinases, such as p38 kinase and protein kinase C.
METHODS:
Phosphatidylserine abundance at the erythrocyte surface was quantified from binding of FITC-labelled annexin-V, cell volume from forward scatter, [Ca2+]i from Fluo3-fluorescence, and reactive oxygen species (ROS) from 2',7'-dichlorodihydrofluorescein diacetate (DCFDA) fluorescence.
RESULTS:
A 48 h treatment of human erythrocytes with zosuquidar significantly increased the percentage of annexin-V-binding cells (2 and 4 µg/ml), significantly decreased forward scatter (4 µg/ml), significantly increased [Ca2+]i (4 µg/ml), but did not significantly modify ROS. The up-regulation of annexin-V-binding following zosuquidar (4 µg/ml) treatment was significantly blunted by removal of extracellular Ca2+, by presence of p38 kinase inhibitor SB203580 (2 µM) and by presence of protein kinase C inhibitor calphostin (100 nM).
CONCLUSIONS:
Exposure of erythrocytes to zosuquidar triggers suicidal erythrocyte death with erythrocyte shrinkage and erythrocyte membrane scrambling, an effect involving Ca2+ entry and requiring activity of SB203580 and calphostin sensitive kinases.
